

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions.
You can purchase shares of NeuroPace (NASDAQ:NPCE) through any online brokerage.
Other companies in NeuroPace’s space includes: Abbott Laboratories (NYSE:ABT), Intuitive Surgical Inc (NASDAQ:ISRG), Medtronic PLC (NYSE:MDT), Stryker Corp (NYSE:SYK) and Boston Scientific Corp (NYSE:BSX).
NeuroPace has a consensus price target of $17.69.
The stock price for NeuroPace (NASDAQ: NPCE) is $12.69 last updated November 10, 2026 at 4:00 PM EST.
There are no upcoming dividends for NeuroPace.
NeuroPace does not have any upcoming earnings scheduled.
There is no upcoming split for NeuroPace.
NeuroPace is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that...